DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

AGN-199201 for the Treatment of Erythema With Rosacea

Phase 2

Completed

Conditions: Rosacea
Erythema

Interventions: Drug: AGN-199201 Vehicle
Drug: AGN-199201 Dose B
Drug: AGN-199201 Dose A
Drug: AGN-199201 Dose C

First Posted Date: 2012-11-28

Last Posted Date: 2019-11-18

Lead Sponsor: Allergan

Target Recruit Count: 357

Registration Number: NCT01735201

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Phase 4

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug: Alcaftadine 0.25%
Drug: Olopatadine 0.2%

First Posted Date: 2012-11-26

Last Posted Date: 2014-01-14

Lead Sponsor: Allergan

Target Recruit Count: 157

Registration Number: NCT01732757

An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: OPTIVE PLUS®

First Posted Date: 2012-10-22

Last Posted Date: 2014-03-17

Lead Sponsor: Allergan

Target Recruit Count: 1209

Registration Number: NCT01711424

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Phase 3

Completed

Conditions: Idiopathic Eyelash Hypotrichosis

Interventions: Drug: bimatoprost formulation A solution
Drug: bimatoprost solution 0.03 %
Drug: vehicle of bimatoprost formulation A solution
Drug: vehicle of bimatoprost solution 0.03 %

First Posted Date: 2012-10-03

Last Posted Date: 2015-02-10

Lead Sponsor: Allergan

Target Recruit Count: 464

Registration Number: NCT01698554

An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine

Completed

Conditions: Migraine Disorders

Interventions: Drug: botulinum toxin Type A

First Posted Date: 2012-09-18

Last Posted Date: 2018-11-09

Lead Sponsor: Allergan

Target Recruit Count: 641

Registration Number: NCT01686581

Locations: 🇩🇪
Kathrin Krome, Bamberg, Germany
🇩🇪
Ulrike Kirchhöfer, Erfurt, Germany
🇩🇪
Hans-Dieter Zug, Böblingen, Germany

and more 74 locations

Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye

Phase 4

Completed

Conditions: Dry Eye

Interventions: Device: Punctal Plug

First Posted Date: 2012-09-13

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 30

Registration Number: NCT01684436

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Not Applicable

Completed

Conditions: Moderate to Severe Nasolabial Folds

Interventions: Device: Crosslinked hyaluronic acid dermal filler

First Posted Date: 2012-09-07

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 70

Registration Number: NCT01680497

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

Phase 2

Terminated

Conditions: Neuralgia, Postherpetic

Interventions: Drug: AGN-214868
Drug: AGN-214868 Placebo (Vehicle)

First Posted Date: 2012-09-05

Last Posted Date: 2020-01-07

Lead Sponsor: Allergan

Target Recruit Count: 280

Registration Number: NCT01678924

Locations: 🇵🇱
NZOZ Neuro-Kard, Poznan, Poland
🇺🇸
University of California, Irvine, Irvine, California, United States
🇦🇹
Wilhelminenspital der Stadt Wien, Wien, Austria

and more 65 locations

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A
Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops

First Posted Date: 2012-08-14

Last Posted Date: 2015-09-21

Lead Sponsor: Allergan

Target Recruit Count: 460

Registration Number: NCT01664949

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

Phase 3

Completed

Conditions: Migraine Disorders

Interventions: Drug: Placebo (Normal Saline)
Biological: Botulinum toxin type A Dose 1
Biological: Botulinum toxin type A Dose 2

First Posted Date: 2012-08-10

Last Posted Date: 2017-09-05

Lead Sponsor: Allergan

Target Recruit Count: 125

Registration Number: NCT01662492

Locations: 🇺🇸
New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸
Texas Association of Pediatric Neurology/Road Runner Research, San Antonio, Texas, United States

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy